Peptides DB
Research-centric peptide and protocol reference hub

Zenagamtide record · updated 6h ago

Metabolic & appetiteGrade A · human clinicalResearch use only
All 17 studiesJump to the evidenceCompare
What is Zenagamtide used for?

Research peptide discovered via AI researcher. research peptide

How it works: GLP-1 and amylin receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Zenagamtide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 7 registered trials. It describes the research record, not a recommendation.

Identity
NameZenagamtide
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMetabolic
Research levelWell Studied
Discovered byThe Librarian · 2026
Pharmacology
MechanismGLP-1 and amylin receptor agonist
RouteSubcutaneous injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 8, 2026. How this works →
Research stats
Total studies17
Human / animal / cellular10 / 2 / 1
Highest trial phasePhase 4
Years covered2023–2026
Latest study15d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

17 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Targeting oxidative stress-NLRP3-apoptotic-steroidogenic axis in doxorubicin-induced testicular toxicity: protective efficacy of ferulic acid niosomes.
FindingNot reported in abstract.
Animal2026Full text read0.70
Lymphatic Targeting of Flubendazole via Long-Chain Fatty Acid Nanoemulsion: Pharmacokinetic Evidence of Chylomicron-Mediated Uptake in Rats.
FindingC_max = 2.42 ± 0.34 μg/mL for FLZ-NE
Animal2026Full text read0.80
Obstructive Sleep Apnea: Epidemiology, Pathophysiology, Complications, Diagnosis, Management, and Emerging Fibrosis-Linked Remodeling.
TakeawayOSA is a complex systemic disease with potential fibrosis-linked remodeling effects, requiring more nuanced diagnostic metrics than currently used.
review2026Full text read0.80
Application of Clinical Indicators in the Early Prediction of Refractory <i>Mycoplasma pneumoniae</i> Pneumonia in Children: A Retrospective Study.
FindingThe combined model's area under the curve was 0.946.
Human2026Full text read0.80
Risk factors associated with malnutrition in elderly patients with chronic heart failure.
FindingArea under the curve of 0.902 for the final model.
Human2024Full text read0.80
Subfoveal Choroidal Thickness is Independently Associated with Axial Length and Myopia in Preschool Children: A Swept-Source Optical Coherence Tomography Study.
FindingMean SFCT was 326.33 ± 43.01 μm in children aged 3-6 years.
Human2026Full text read0.90
Effects of the combination therapy of hemodialysis with hemoperfusion on medium molecular toxins and protein bound uremic toxins in maintenance hemodialysis patients.
Findingβ2-MG reduced from 29.72±5.61 to 21.50±6.69 μg/ml, t=5.882, P<0.001
Human2026Full text read0.80
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
TakeawayNot reported in abstract.
—2026Title only0.10
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
TakeawayNot reported in abstract.
—2026Title only0.10
Transcriptomic and Metabolomic Analysis Reveals the Molecular Mechanisms of the Impact on the Fruiting Body Phenotype of &lt;i&gt;Lentinula edodes&lt;/i&gt; Under Different Light Conditions.
Finding228.12 g productivity per log under blue light.
In vitro2026Full text read0.70
Effects of remimazolam vs. propofol on plasma neurofilament light chain and postoperative delirium in frail elderly patients undergoing major non-cardiac surgery: a prospective, randomized, assessor-blinded controlled trial.
FindingPlasma NfL concentrations on postoperative day 1 were 123.3[83.6-198.2] pg/ml for Group R and 149.0[102.0-226.6] pg/ml for Group P, P=0.186.
Human2026Full text read0.80
Environmental classification of synthetic methods for zinc oxide nanoparticles: a comparative review of sustainable green and conventional approaches with their diverse applications.
TakeawayThis review highlights the trade-offs between performance and environmental impact in the synthesis of zinc oxide nanoparticles, advocating for a hybrid approach that combines precision and sustainability.
review2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Zenagamtide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Zenagamtide is discussed should be drawn from it.